Research summary
VIP has been studied in cell, animal and limited clinical research on pulmonary vascular, gastrointestinal and immune function, and its short half-life has led to work on stabilised analogues. This summary describes what the literature has investigated. It is not a claim about the effects of our product, which is supplied for laboratory research only.
Mechanism of action
VIP (vasoactive intestinal peptide) is a 28-amino-acid neuropeptide that signals through the VPAC1 and VPAC2 receptors, which are class B G protein-coupled receptors coupled to cyclic AMP. Published work has examined its roles in smooth muscle relaxation, immune regulation and neuroendocrine signalling.
Chemical properties
Sequence: His-Ser-Asp-Ala-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn (28 residues). Molecular weight: approx. 3326 g/mol. Form: lyophilised powder. Purity and identity: see the batch Certificate of Analysis (HPLC and mass spectrometry).
Storage and handling
Supplied as a lyophilised (freeze-dried) powder. Store sealed, cold, dry and protected from light, as stated on the Certificate of Analysis and product label. Allow the vial to reach room temperature before opening to limit condensation. Avoid repeated temperature cycling and humidity exposure. For laboratory research use only.
Literature references
Selected PubMed records on vasoactive intestinal peptide (VIP), scientific background only, not claims about our product. PMID 26702849: VIP, PACAP and their receptors in cancer (review). PMID 35770640: VIP as a potential target for antiviral therapy (review). Open any record at https://pubmed.ncbi.nlm.nih.gov/PMID/ . More: https://pubmed.ncbi.nlm.nih.gov/?term=vasoactive+intestinal+peptide
For laboratory research use only. Not for human or veterinary use. Nothing on this page is medical advice.
